EUVIMEDEUVIMED entdecken
Open Access

Association of adverse effects with high serum posaconazole concentrations

Kelsey Jensen iD, Omar Abu Saleh, Supavit Chesdachai iD, Paul J Jannetto, Kristin C Mara, Zachary A Yetmar, Christina G Rivera

Medical Mycology · 02.08.2023 · 61 (8)

DOI: 10.1093/mmy/myad079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Mycology, online erschienen am 03.08.2023. Verfasst von Kelsey Jensen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic Health System, Austin, MN, USA. Hauptthemen laut MEDLINE: Invasive Fungal Infections, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Mayo Clinic, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Posaconazole therapeutic drug monitoring (TDM) is widely utilized to assess therapeutic efficacy and safety; however, clinical effects of very high serum concentrations are unknown. A retrospective review of 90 patients receiving posaconazole for treatment or prophylaxis of invasive fungal infections with serum concentrations ≥3000 ng/mL from 1/1/2019 to 4/30/2021 evaluated the incidence and type of adverse drug reactions (ADRs). Symptomatic ADRs were very common in patients with posaconazole concentrations of ≥5000 ng/mL and 3000–4999 ng/mL (80% vs. 58.8%; P = 0.31). Posaconazole TDM should be performed for both treatment and prophylaxis indications and dose decrease for serum concentrations >3000 ng/mL should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Invasive Fungal InfectionsDrug-Related Side Effects and Adverse ReactionsAnimalsAntifungal AgentsRetrospective StudiesTriazoles

Stichwörter der Autor:innen

drug monitoringposaconazoleposaconazole toxicitysupratherapeutic posaconazoletriazoles

Substanzen

Antifungal AgentsposaconazoleTriazoles

Autor:innen und Institutionen

  • Department of Pharmacy, Mayo Clinic Health System, Austin, MN, USA.
  • Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Kelsey Jensen, Supavit Chesdachai

Förderung

  • NCATS NIH HHS
  • Mayo Clinic
  • National Center for Advancing Translational Sciences
  • NIH

Zitieren

APA

Jensen, K., Saleh, O. A., Chesdachai, S., Jannetto, P. J., Mara, K. C., Yetmar, Z. A., & Rivera, C. G. (2023). Association of adverse effects with high serum posaconazole concentrations. Medical Mycology, 61(8). https://doi.org/10.1093/mmy/myad079

Vancouver

Jensen K, Saleh OA, Chesdachai S, Jannetto PJ, Mara KC, Yetmar ZA, et al. Association of adverse effects with high serum posaconazole concentrations. Medical Mycology. 2023;61(8). doi:10.1093/mmy/myad079

BibTeX
@article{Jensen2023,
  author = {Jensen, Kelsey and Saleh, Omar Abu and Chesdachai, Supavit and Jannetto, Paul J and Mara, Kristin C and Yetmar, Zachary A and Rivera, Christina G},
  title = {Association of adverse effects with high serum posaconazole concentrations},
  journal = {Medical Mycology},
  year = {2023},
  volume = {61},
  number = {8},
  doi = {10.1093/mmy/myad079}
}
Kostenlos starten →